Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite

Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite var callbackToken='475B5DDB295DAA5'; Skip to main page content HOME CURRENT ISSUE ARCHIVE FEEDBACK SUBSCRIPTIONS ALERTS HELP Keywords GO Advanced » Institution: DeepDyve Sign In as Member / Individual User Name Password Sign In Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite Anthony G. Borel , Timothy M. Jones , Robert J. Barbuch , David A. Jackson , Palaniappan Kulanthaivel , Edward Mattiuz , Valentine J. Klimkowski , William J. Wheeler 1 and Gregory A. Rener Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana <h3>Address correspondence to:</h3> Dr. Anthony G. Borel, Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: aborel@lilly.com ↵ 1 Current affiliation: IsotopicSolutions, LLC, Indianapolis, Indiana. <h2>Abstract</h2> 2-Methylalanyl- N -{1-[(1 R )-1-(4-fluorophenyl)-1-methyl-2-oxo-2-pyrrolidin-1-ylethyl]-1 H -imidazol-4-yl}-5-phenyl- d -norvalinamide (LY654322) was rapidly cleared in rats and dogs by renal excretion of parent and metabolism (oxidative and hydrolytic). Among the metabolites identified in the urine of rats and dogs was M25, which was structurally unusual. Indeed, the characterization of M25 and investigation into its disposition relied on the convergence of diverse analytical methodologies. M25 eluted http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drug Metabolism and Disposition Am. Soc for Pharma & Experimental Therapeutics

Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite

Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite

Drug Metabolism and Disposition , Volume 39 (5): 740 – May 1, 2011

Abstract

Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite var callbackToken='475B5DDB295DAA5'; Skip to main page content HOME CURRENT ISSUE ARCHIVE FEEDBACK SUBSCRIPTIONS ALERTS HELP Keywords GO Advanced » Institution: DeepDyve Sign In as Member / Individual User Name Password Sign In Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite Anthony G. Borel , Timothy M. Jones , Robert J. Barbuch , David A. Jackson , Palaniappan Kulanthaivel , Edward Mattiuz , Valentine J. Klimkowski , William J. Wheeler 1 and Gregory A. Rener Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana <h3>Address correspondence to:</h3> Dr. Anthony G. Borel, Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: aborel@lilly.com ↵ 1 Current affiliation: IsotopicSolutions, LLC, Indianapolis, Indiana. <h2>Abstract</h2> 2-Methylalanyl- N -{1-[(1 R )-1-(4-fluorophenyl)-1-methyl-2-oxo-2-pyrrolidin-1-ylethyl]-1 H -imidazol-4-yl}-5-phenyl- d -norvalinamide (LY654322) was rapidly cleared in rats and dogs by renal excretion of parent and metabolism (oxidative and hydrolytic). Among the metabolites identified in the urine of rats and dogs was M25, which was structurally unusual. Indeed, the characterization of M25 and investigation into its disposition relied on the convergence of diverse analytical methodologies. M25 eluted

Loading next page...
 
/lp/am-soc-for-pharma-experimental-therapeutics/metabolism-of-ly654322-a-growth-hormone-secretagogue-to-an-unusual-rwcg6zDlJC

References (16)

Publisher
Am. Soc for Pharma & Experimental Therapeutics
Copyright
Copyright © Drug Metabolism and Disposition
ISSN
0090-9556
eISSN
1521-009X
DOI
10.1124/dmd.110.037598
pmid
21346003
Publisher site
See Article on Publisher Site

Abstract

Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite var callbackToken='475B5DDB295DAA5'; Skip to main page content HOME CURRENT ISSUE ARCHIVE FEEDBACK SUBSCRIPTIONS ALERTS HELP Keywords GO Advanced » Institution: DeepDyve Sign In as Member / Individual User Name Password Sign In Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite Anthony G. Borel , Timothy M. Jones , Robert J. Barbuch , David A. Jackson , Palaniappan Kulanthaivel , Edward Mattiuz , Valentine J. Klimkowski , William J. Wheeler 1 and Gregory A. Rener Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana <h3>Address correspondence to:</h3> Dr. Anthony G. Borel, Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: aborel@lilly.com ↵ 1 Current affiliation: IsotopicSolutions, LLC, Indianapolis, Indiana. <h2>Abstract</h2> 2-Methylalanyl- N -{1-[(1 R )-1-(4-fluorophenyl)-1-methyl-2-oxo-2-pyrrolidin-1-ylethyl]-1 H -imidazol-4-yl}-5-phenyl- d -norvalinamide (LY654322) was rapidly cleared in rats and dogs by renal excretion of parent and metabolism (oxidative and hydrolytic). Among the metabolites identified in the urine of rats and dogs was M25, which was structurally unusual. Indeed, the characterization of M25 and investigation into its disposition relied on the convergence of diverse analytical methodologies. M25 eluted

Journal

Drug Metabolism and DispositionAm. Soc for Pharma & Experimental Therapeutics

Published: May 1, 2011

There are no references for this article.